Highlights CanSino Biologics Inc.

Equities

6185

CNE100003F01

Market Closed - Hong Kong S.E. Other stock markets 04:08:05 2024-05-31 am EDT			5-day change	1st Jan Change
20.35 ^HKD	-3.78%		-7.71%	-13.59%

May. 31	CanSino Biologics Inc. Announces Resignation of Nisa Bernice Wing-Yu LEUNG as Non-Executive Director and Member of the Nomination Committee	CI
May. 21	Cansino Biologics Invests 160 Million Yuan in China Bohai Bank’s Structured Deposits	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Cansino Biologics Invests 160 Million Yuan in China Bohai Bank’s Structured Deposits	May. 21	MT
CanSino Biologics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 29	CI
Cansino Bio Gets Nod for China Clinical Trials of Haemophilus Influenzae Vaccine	Apr. 22	MT
CanSino Biologics Inc. Obtains Clinical Trial Approval Granted by the National Medical Products Administration of the People's Republic of China	Apr. 22	CI
Cansino Biologics Pneumococcal Vaccine's Phase I Trial Offers Positive Results	Apr. 21	MT
Cansino Biologics Begins Phase III Clinical Trials for Tetanus Drug	Mar. 20	MT
Cansino Biologics Inc. Announces Initiation of Phase III Clinical Trial and Completion of First Trial Patient Case for Absorbed Tetanus Vaccine	Mar. 20	CI
CanSino Biologics Sued by Brazilian Pharma Firm Belcher Over COVID-19 Vaccine Dispute	Mar. 14	MT
Cansino Biologics Inc. Announces Acceptance of Drug Registration Application for 13-Valent Pneumococcal Conjugate Vaccine	Feb. 28	CI
CanSino Biologics' Loss Widens in 2023, Misses EPS, Revenue Estimates; Shares Rise 4%	Feb. 26	MT
CanSino Biologics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 23	CI
CanSino Biologics' Loss to Widen in 2023; Shares Drop 5%	Jan. 31	MT
Cansino Biologics Inc. Provides Earnings Guidance for Year Ended December 31, 2023	Jan. 30	CI
CanSino Biologics Inc. Obtains the Final Report of Phase III Clinical Trial Of 13-Valent Pneumococcal Conjugate Vaccine	Jan. 30	CI
Cansino Biologics Inc. Announces Phase I Clinical Trial and Completion of First Patient Case for Recombinant Poliomyelitis Vaccine	Jan. 15	CI
CanSino Biologics Inc. Announces Initiation of Phase I Clinical Trial and Completion of First Trial Patient Case for Absorbed Tetanus Vaccine	Dec. 20	CI
Cansino Biologics Inc. Announces Initiation of Phase I Clinical Trial and Completion of First Patient Enrollment for TDCP Adolescent and Adult	Dec. 06	CI
CanSino Biologics' COVID-19 Vaccine Included for China's Emergency Use	Dec. 04	MT
CanSino Biologics Inc. announces Recombinant Covid-19 Xbb.1.5 Variant Vaccine Forinhalation (Adenovirus Type 5 Vector) Included for Emergency Use	Dec. 03	CI
CanSino Biologics Inc. Announces Initiation of Phase I Clinical Trial and Completion of First Trial Patient Case	Nov. 08	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

INTERVIEW - Xuefeng Yu, CEO of CanSino Biologics: Behind the scenes of the agreement with AstraZeneca

August 31, 2023 at 06:08 am EDT